TERN Terns Pharmaceuticals, Inc.
Q3 2025 10-Q
Terns Pharmaceuticals, Inc. (TERN) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 10, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New regulatory risk: FDA workforce cut by 3,500 employees due to HHS reduction in force, risking delays in drug review and approvals
- • Most updated risk: Escalation of U.S.-China tariffs and trade tensions, including possible 100% tariff on imported branded drugs from Oct 2025
Quarterly Financial SummaryXBRL
Net Income
-$542,000
▼ -168.5% YoY▼ -193.0% QoQ
ROE
-0.2%
Total Assets
$302M
EPS (Diluted)
$-0.27
▲ +3.6% YoY▼ -3.8% QoQ
Operating Cash Flow
-$20M
▼ -20.2% YoY▼ -4.7% QoQ
Source: XBRL data from Terns Pharmaceuticals, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Terns Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.